Pathologic and therapeutic evaluation of irritable bowel syndrome and ulcerative colitis

Pathologic and therapeutic evaluation of irritable bowel syndrome and ulcerative colitis - Investigation of irritable bowel syndrome and ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004128

Enrollment

200

Registered

2010-08-31

Start date

2015-11-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome and ulcerative colitis

Interventions

Treat patient with irritable bowel syndrome using 5ug/day 5HT3 receptor antagonist and ulcerative colitis using 10ug/day for 4weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with irritable bowel syndrome, ulcerative colitis and sex and age matched controls who plan colonoscopy

Exclusion criteria

Exclusion criteria: Using SSRI or prokinetics. Patients with constipation, hemorrhagic diseases, insulin-dependent diabetes mellitus, cirrhosis or renal failure.

Design outcomes

Primary

Measure	Time frame
Improvement of symptoms	—

Secondary

Measure	Time frame
Compare serotonin or serotonin related gene expression and polymorphisms among the patients with irritable bowel syndrome, ulcerative colitis and sex and age matched controls to identify the predictive factors for the effectiveness of 5-HT3 receptor antagonist	—

Countries

Japan

Contacts

Public ContactMs. Yamazi

Kawasaki Medical School Research support

kmsrec@med.kawasaki-m.ac.jp81864621111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026